ACRIA Studies in Progress

• Crofelemer for Diarrhea
• Avandia and Serostim
• KP-1461
• SPRING: Aptivus in Diverse Populations
• IMPACT: Reyataz Resistance
• CHAMPS
• Ibalizumab
• Prezista Dosing
• Etravirine (TMC 125) Expanded Access (Closed to Enrollment)
• Transacin (NGX-4010) (Closed to Enrollment)
• TH9507 (Closed to Enrollment)

Crofelemer for Diarrhea

People 18 and older who have persistent diarrhea will first take crofelemer or placebo tablets for 6 weeks. Then everyone will take crofelemer for 5 months.

Avandia and Serostim

People with insulin resistance will take Avandia (rosiglitazone), or Serostim (growth hormone), or both for 6 months to see how they affect glucose, insulin levels and body shape.

KP-1461

People aged 18-60 who have taken an NRTI, NNRTI and PI, and have developed resistance or stopped the drugs for other reasons, will take KP-1461 (a new type of NRTI) with no other ARVs for four months.

SPRING: Aptivus in Diverse Populations

People 18 and older (half white and half non-white, half men and half women) who have taken an NRTI, NNRTI and PI (not Aptivus) and who have resistance to at least two PIs, will take a standard dose of Aptivus or receive therapeutic drug monitoring to find the best dose for them.

IMPACT: Reyataz Resistance

People who have developed resistance to Reyataz will come in for one day of blood tests to study the I50L mutation.

CHAMPS

People aged 18 and over who have resistance to at least three classes of HIV meds will take either maraviroc (Selzentry) or INCB 9471, a new once-per-day CCR5 inhibitor.

Ibalizumab

In addition to oral HIV meds, people will be given IV infusions of placebo or one of four doses of ibalizumab, a monoclonal antibody designed to block HIV entry.

Prezista Dosing

People 18 and older who have been taking HIV meds for at least 12 weeks will take Prezista with Norvir either once a day or twice a day, along with other HIV meds.

For more information on these trials, contact us at 212-924-3934 ext. 121.

Etravirine (TMC 125) Expanded Access (Closed to Enrollment)

People 18 and older who have limited treatment options and resistance to approved NNRTIs, and who have taken an NRTI, NNRTI and at least two PIs, may qualify for early access to this experimental NNRTI.

Transacin (NGX-4010) (Closed to Enrollment)

People with HIV who have peripheral neuropathy will use either Transacin (capsaicin) patches or very low-dose patches for 30 or 60 minutes a day for 3 months. Participants must be 18 or older and have had pain in both feet for at least 2 months.

TH9507 (Closed to Enrollment)

People aged 18-65 who have excess abdominal fat will take either TH9507 (an investigational growth hormone releasing factor), or a placebo for 26 weeks. The two groups will then switch for 26 more weeks.